97980-65-9

Basic information

• Product Name: Acetic acid, [(4-oxo-2-phenyl-4H-1-benzopyran-7-yl)oxy]-
• CAS NO: 97980-65-9
• Molecular Formula: C17H12O5
• Molecular Weight: 296.279
• Mol File: 97980-65-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Acetic acid, [(4-oxo-2-phenyl-4H-1-benzopyran-7-yl)oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, [(4-oxo-2-phenyl-4H-1-benzopyran-7-yl)oxy]-(97980-65-9)
• EPA Substance Registry System: Acetic acid, [(4-oxo-2-phenyl-4H-1-benzopyran-7-yl)oxy]-(97980-65-9)

Safety Data

• Hazardous Substances Data: 97980-65-9(Hazardous Substances Data)

Upstream product

• 98-88-4 benzoyl chloride 
• 5465-06-5 <4-(benzoyloxy)-2-hydroxybenzoyl>benzoylmethane 
• 38256-07-4 1-(2',4'-dihydroxyphenyl)-3-phenyl-propane-1,3-dione 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 6665-86-7 7-hydroxyflavone 
• 2430-55-9 7-ethoxy-carbonylmethoxyflavanone 
• 119-41-5 7-ethoxycarbonylmethoxyflavone 

Downstream Products

• 301206-12-2 N-(6-amino-3-methyl-2,4-dioxo-1-phenyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-(4-oxo-2-phenyl-4H-chromen-7-yloxy)-acetamide 
• 119-41-5 7-ethoxycarbonylmethoxyflavone 

Relevant articles and documents

Synthesis and biological evaluation of Complex I inhibitor R419 and its derivatives as anticancer agents in HepG2 cells

In this study, Complex I inhibitor R419 was firstly revealed to have significant anticancer activity against HepG2 cells (IC50 = 5.2 ± 0.9 μM). Based on this finding, a series of R419 derivatives were synthesized and biologically evaluated. As results, 9 derivatives were found to have obvious anticancer activity. Among them, H20 exhibited the most potent activity (IC50 = 2.8 ± 0.4 μM). Mechanism study revealed that H20 caused severe depletion of cellular ATP, dose-dependently activated AMPK, decreased Bcl-2/Bax ratio and induced necrotic cell death. Most importantly, H20 displayed definite inhibitory activity against Complex I.

Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction

In order to find novel nonsteroidal compounds possessing an inhibitory activity against delayed-type hypersensitivity (DTH) reactions, we conducted random screening using a picryl chloride (PC)-induced contact hypersensitivity reaction (CHR) in mice, and found compound 1 as a lead compound. Then we synthesized and evaluated an extensive series of 5-carboxamidouracil derivatives focused on both the uracil and the antioxidative moieties. Among them, we found that the hindered phenol moiety was necessary to exhibit the activities; especially, compounds 28a-28c having the partial structure of vitamin E were found to exert potent activities against the DTH reaction by both oral and topical administration. And compound 28c showed antioxidative activity against lipid peroxidation with an IC50 of 5.9μM. Compound 28c (CX-659S) was chosen as a candidate drug for the treatment of cutaneous disorders such as atopic dermatitis and allergic contact dermatitis. Copyright (C) 2000 Elsevier Science Ltd.